ArticleScientific reports2026
A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human antibody repertoire is a promising source for therapeutic-grade antibodies. Yet current methods for strategically mining these B cell repertoires are stymied by throughput and chain pairing considerations. This study presents advancements in fluidics and molecular biology that enable the multi-step encapsulation and capture of B cells from an immunized, humanized mouse in nanoliter sized droplets. Once singularly captured, antigen-specific B-cells can be lysed and individually manipulated via RT-PCR to splice cognate V genes and create a predominantly natively paired library. To explore the importance of these process improvements in library generation, we constructed natively-paired libraries against two therapeutically-relevant human proteins. Through deep sequencing, bioinformatics-driven screening and phage display, we selected functional, target-specific antibodies. Our findings reveal that natively paired libraries contain a higher percentage of target-specific antibodies and demonstrate enhanced potency and improved developability in both in silico and in vitro assessments relative to combinatorial library-derived antibodies. Furthermore, antibodies with native pairing show increased potency as well as improved in silico and in vitro developability compared to their randomly paired counterparts. To this end, we see this droplet microfluidic platform and its capacity to generate and facilitate the high-throughput interrogation of antigen-specific antibody repertoires as an important, orthogonal therapeutic antibody discovery approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.